🔗 Share this article

As the US continues making unprecedented adjustments to its vaccination guidelines, one figure has emerged somewhat surprisingly: Tracy Beth Høeg, an American of Danish descent physician and epidemiologist who rose to prominence by expressing skepticism about COVID-19 shots during the global health crisis and has concentrated on potential fatalities after COVID-19 immunization in her short time at the FDA.

Proposed Shifts to Childhood Immunization Schedule

Health officials were set to unveil sweeping revisions to the pediatric vaccine schedule earlier this month, bringing the US with the Danish vaccine program, it is understood – a significant shift that would put the US out of alignment with much of the global community with little proof for benefit. The announcement has been postponed until the new year.

Instead of Vinay Prasad, Høeg is scheduled to speak at the event. She was recently named acting director of the FDA’s CDER, the fifth person to run the office this calendar year.

A Shift at the Regulatory Body

Høeg's temporary position may indicate a tighter collaboration between the drug and biologics divisions as Dr. Høeg and Prasad consolidate power at the regulatory agency – and it suggests a renewed priority upon dismantling already-approved vaccines at the FDA.

Dr. Høeg has frequently advocated for discontinuing specific pediatric vaccine recommendations in the US to become more similar to the Danish model, a country with nationalized medicine and a citizenry roughly the size of Wisconsin’s.

To date statements, she has kept her attention on immunizations – typically the responsibility of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than drug regulation.

Doubts Over Background

The appointee has no apparent background in medication creation, oversight or management, which has been typical for former directors of the CBER. She has been employed at the FDA as a top consultant to the agency head and the vaccine center since March.

“She appears not to have the necessary background” for running the pharmaceutical oversight division, remarked Jonathan Howard. “She lacks experience running a randomized controlled trial. She is not versed in leading a major agency. She lacks background in industry regulation.”

Former directors of CBER would “understand regulatory frameworks and the science of drug development”, commented a former acting FDA commissioner. “Clearly, she has not acquired the type of experience that prior appointees who headed CBER have had.”

CDER has an enormous portfolio at the agency, Woodcock pointed out.

“Many people just zeroes in on the new drug program, but the off-patent medication office authorizes numerous generic drugs. There is also a biosimilars division, non-prescription drug unit and more, and each of these must be looked after,” she noted. “The area you don’t keep your eye on, that’s the thing that I always told people is going to come back to haunt you.”

Additionally, a substantial management component to the job, which manages in excess of 5,000 staff members. “It is a huge administrative position, if you do it right,” she added.

Official Statement and Disputed Initiatives

In response to inquiries about Høeg’s fitness for the role and whether this assignment indicates increased cooperation among regulatory chiefs on immunizations, a representative responded that the “concerns stem from flawed assumptions”.

“This background matches the responsibilities of her role,” the official said, citing the period Dr. Høeg spent guiding the agency head on “medication safety and oversight research, including computational safety modeling and immunization monitoring”.

As the temporary head, Dr. Høeg inherits the agency head's new expedited review system, a disputed one-day therapy clearance system that apparently troubled her predecessors. “By what process are these medications being selected for this expedited pathway? Who makes the decisions?” Howard asked. “There’s a lot of secrecy occurring at the FDA right now.”

Overall, he stated, “the agency seems to be moving towards less stringent regulations of pharmaceuticals, except for immunizations.”

Established Past Work on Immunizations

Regarding vaccines, Dr. Høeg has a more established, if troubling, past, some experts have noted. She released a study using unverified crowd-sourced reports to estimate the incidence of myocarditis after COVID-19 immunization. She counseled the state of Florida top health official Joseph Ladapo, who was said to have altered data to indicate COVID-19 vaccinations are more dangerous than they are.

Part of her “desired changes” for the current federal leadership encompassed revising guidelines for recently developed shots and ending “unnecessary” vaccines, she said after the election on a online show. At the agency, Høeg has allegedly suggested barring young men from obtaining Covid vaccines.

“She’s an all-around dogmatist who begins with her preconceived notions and tailors the evidence to retrofit the evidence in a highly misleading, dishonest fashion,” Howard said.

Taking Control and a “Campaign of Retribution”

Høeg joined other contrarians, {like|